Oncology AACR 2025: New modalities and remaining challenges Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges
News AACR 2025: Quintet of investigational oncological drugs puts... Ascentage Pharma, specialising in haematological malignancies, has presented results from five preclinical studies at AACR 2025.
News AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncol... Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at AACR 2025.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
